TLC178 designated by US FDA as drug for rare paediatric disease in the treatment of Rhabdomyosarcoma

TLC178 designated by US FDA as drug for rare paediatric disease in the treatment of Rhabdomyosarcoma By Laxmi Iyer - April 26, 2017 | | See Original Here Taiwan Liposome Company, Ltd.,(TLC) (4152:TT) today announced that its oncology drug candidate TLC178 has been designated as a drug for a rare pediatric disease in the treatment of rhabdomyosarcoma…
Continue Reading »

Cancer Math and Rhabdomyosarcoma: Crowdfunding Request

Cancer Math and Rhabdomyosarcoma: Using engineering principles to develop personalized therapies for patients with rhabdomyosarcoma Last year Dr. Noah Berlow, a Postdoctoral Fellow at the Children's Cancer Therapy Development Institute (c-TDI) presented a webinar on the work he is doing in cancer math. With the reductions in federal research funding - and much greater cuts…
Continue Reading »

Childhood Cancer Survivors: Genetic Risk for Future Cancers?

Childhood Cancer Survivors: Genetic Risk for Future Cancers? Kate Johnson | April 05, 2017 | Medscape Medical News | See Original Here WASHINGTON – Almost 12% of childhood cancer survivors have genetic mutations that put them – or their children – at risk for future cancers, according to the first large-scale whole-genome sequencing study in this patient population. The…
Continue Reading »

New Blood Test May Pinpoint Cancer Tumors

New Blood Test May Pinpoint Cancer Tumors Written by Honor Whiteman | Healthline News |Published on March 6, 2017 | See Original Here Researchers say using DNA signatures may provide a diagnostic tool for cancer that isn't invasive.   New research shows promise for a blood test that not only identifies cancer but also pinpoints precisely where…
Continue Reading »

Instead of starving a cancer, researchers go after its defenses

Instead of starving a cancer, researchers go after its defenses Oxygen deprivation can propel tumor growth and spread BY LAURA BEIL | FEBRUARY 22, 2017 | ScienceNews | See Original Here | Magazine issue: Vol. 191 No. 4, March 4, 2017, p. 24 Oxygen Depreivation: Cancer cells (shown in blue) surround a blod vessel (red) in a mouse tumor. ells…
Continue Reading »

Immunotherapy: Could the Human Body Be Trained to Fight Cancer?

Immunotherapy: Could the Human Body Be Trained to Fight Cancer? Live Science - Health | By Balveen Kaurand  & Pravin Kaumaya, The Ohio State University | February 5, 2017 07:34am ET | See Original Here This article was originally published at The Conversation. The publication contributed the article to Live Science's Expert Voices: Op-Ed & Insights. The human immune…
Continue Reading »

New clinical trial (not yet open) to watch

Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma See Original Notice Here Identifier: NCT03041701 Sponsor: National Cancer Institute (NCI) Background: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood. Two types are embryonal RMS (ERMS) and alveolar…
Continue Reading »

Focus On Rhabdo Webinar Series – March 5, 2017 – Dr. Zoë Walters

Focus On Rhabdo Webinar Series March 5, 2017 Dr. Zoe Walters - Institute of Cancer Research Epigenetics describes the study and role of specific markers on DNA and associated histone proteins. The work that Zoë has undertaken within Janet’s team at the ICR and during her CWCUK fellowship has focused on the role of proteins…
Continue Reading »

Potential new drug class hits multiple cancer cell targets, boosting efficacy and safety

Potential new drug class hits multiple cancer cell targets, boosting efficacy and safety Date: February 1, 2017 | Source: University of California San Diego Health Sciences | See Original Here Summary: A potential new class of anti-cancer drugs inhibits two or more molecular targets at once, maximizing therapeutic efficiency and safety, report scientists. MYC is…
Continue Reading »
Skip to toolbar